Creatinine

Creatinine

SCHEMBL4955889

CC(=O)C(=O)O.CN1CC(=O)NC1=N

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.47
GAA P10253 1/20 0.33
TOP2A P11388 1/20 0.31
TOP2B Q02880 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
PKM P14618 1/20 0.31
NPC1 O15118 1/20 0.30
CYP3A4 P08684 1/20 0.30
GRM5 P41594 1/20 0.30
RAB9A P51151 1/20 0.30
GRM1 Q13255 1/20 0.30
FTO Q9C0B1 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Creatinine SCHEMBL7735944 0.92 CRBN (0.50) CRBNGAATOP2ATOP2BALDH1A1
Creatinine SCHEMBL15323589 0.92 CRBN (0.40) CRBNGAA
Creatinine SCHEMBL15732942 0.90 CRBN (0.52) CRBNGAATOP2ATOP2BALDH1A1
Creatinine SCHEMBL27811809 0.90 CRBN (0.52) CRBNGAATOP2ATOP2BALDH1A1
Creatinine SCHEMBL2248139 0.90 CRBN (0.56) CRBNGAATOP2ATOP2BALDH1A1
Creatinine SCHEMBL28491793 0.86 CRBN (0.56) CRBNGAATOP2ATOP2BALDH1A1
Creatinine SCHEMBL16295 0.86
Creatinine SCHEMBL288087 0.86 CRBN (0.61) CRBNGAATOP2ATOP2BALDH1A1
Creatinine SCHEMBL8637084 0.84
Creatinine SCHEMBL2922002 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230201115-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS THERMOLIFE INTERNATIONAL, LLC 2023-06-29 US disclosed
US-20230062170-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS THERMOLIFE INTERNATIONAL, LLC 2023-03-02 US disclosed
US-11154499-B2 Creatine and/or creatinine compositions and related methods THERMOLIFE INTERNATIONAL, LLC (US) 2021-10-26 US disclosed
US-20210251895-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS THERMOLIFE INTERNATIONAL, LLC 2021-08-19 US disclosed
US-20200246262-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS THERMOLIFE INTERNATIONAL, LLC (US) 2020-08-06 US disclosed
WO-2019191338-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS THERMOLIFE INTERNATIONAL, LLC (US) 2019-10-03 WO disclosed
US-20190298667-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS THERMOLIFE INTERNATIONAL, LLC 2019-10-03 US disclosed
US-20080146633-A1 COMPOSITIONS FOR SKIN LIGHTENING AND TONING DOWN PIGMENT DISORDERS, COMPRISING CREATININE AND/OR CREATININE DERIVATIVES AS ACTIVE SUBSTANCES GOLDSCHMIDT GMBH (DE) 2008-06-19 US disclosed
US-20030180237-A1 Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances GOLDSCHMIDT AG (DE) 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200246262-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS MB, CKMT1A; CKMT1B, REN CRBN 225/4885GAA 806/4885TOP2A 1856/4885
US-11154499-B2 Creatine and/or creatinine compositions and related methods MB, CKMT1A; CKMT1B, REN CRBN 225/4885GAA 806/4885TOP2A 1856/4885
US-20030180237-A1 Compositions for skin lightening and toning down pigment disorders, comprising creatinine and/or creatinine derivatives as active substances ALDH1A2, RBP1, ARSA CRBN 866/4885GAA 1459/4885TOP2A 1038/4885
US-20190298667-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS CKMT1A; CKMT1B, REN, ALB CRBN 591/4885GAA 958/4885TOP2A 2692/4885
US-20230201115-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS CKMT1A; CKMT1B, REN, ALB CRBN 842/4885GAA 514/4885TOP2A 2223/4885
US-20230062170-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS CKMT1A; CKMT1B, REN, ALB CRBN 591/4885GAA 958/4885TOP2A 2692/4885
US-20210251895-A1 CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS MB, CKMT1A; CKMT1B, REN CRBN 225/4885GAA 806/4885TOP2A 1856/4885
US-20080146633-A1 COMPOSITIONS FOR SKIN LIGHTENING AND TONING DOWN PIGMENT DISORDERS, COMPRISING CREATININE AND/OR CREATININE DERIVATIVES AS ACTIVE SUBSTANCES ALDH1A2, REN, ADH1B CRBN 733/4885GAA 1380/4885TOP2A 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.